Dexmedetomidine: pediatric pharmacology, clinical uses and safety

被引:71
|
作者
Su, Felice [1 ]
Hammer, Gregory B. [2 ,3 ]
机构
[1] Stanford Univ, Div Crit Care Med, Dept Pediat, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA
关键词
alpha(2)-agonist; adverse effects; dexmedetomidine; indications; pediatrics; sedation; INTENSIVE-CARE-UNIT; DOSE DEXMEDETOMIDINE; CARDIAC-SURGERY; ALPHA(2A)-ADRENERGIC RECEPTOR; HYPNOTIC RESPONSE; INTRAVENOUS DEXMEDETOMIDINE; AGONIST DEXMEDETOMIDINE; INFLAMMATORY RESPONSES; SEVOFLURANE ANESTHESIA; PROCEDURAL SEDATION;
D O I
10.1517/14740338.2010.512609
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Dexmedetomidine is an alpha(2)-adrenoceptor agonist with sedative, anxiolytic and analgesic properties. It is used off-label in pediatric patients due to its efficacy and lack of adverse respiratory effects. Dexmedetomidine may cause severe circulatory complications in adults. Despite its popularity, the safety of dexmedetomidine in the pediatric population has not been extensively studied. Areas covered in this review: This article reviews the current literature (up to 2010) focusing on applications and safety of dexmedetomidine administered to pediatric patients. What the reader will gain: Dexmedetomidine is a useful sedative and anxiolytic drug in the pediatric intensive care unit as well as during diagnostic and therapeutic procedures. Deleterious effects of dexmedetomidine include hypotension and bradycardia. Additionally, hypertension may occur during the "loading dose" or with high infusion rates. Few studies have been performed to evaluate the safety of dexmedetomidine in pediatrics. The development of tolerance and withdrawal has not been studied in children. Take home message: Despite its favorable respiratory profile, dexmedetomidine may cause deleterious cardiovascular effects. Close monitoring of circulatory dynamics and judicious titration is recommended. Further studies are needed to better define adverse effects following long-term infusions as well as in special populations such as pre-term infants.
引用
收藏
页码:55 / 66
页数:12
相关论文
共 50 条
  • [31] Perioperative Uses of Dexmedetomidine
    Jones, Courtney R.
    INTERNATIONAL ANESTHESIOLOGY CLINICS, 2013, 51 (02) : 81 - 96
  • [32] Innovative uses of dexmedetomidine
    Stamenkovic, Dusica M.
    Hassid, Marc
    JOURNAL OF CLINICAL ANESTHESIA, 2007, 19 (08) : 644 - 645
  • [33] Advanced approaches in pediatric clinical pharmacology
    Al-Sallami, Hesham
    Diniz, Andrea
    Sinha, Jaydeep
    Karatza, Eleni
    Allegaert, Karel
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] PEDIATRIC CLINICAL PHARMACOLOGY - PRACTICAL REVIEW
    UDKOW, G
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1978, 132 (10): : 1025 - 1032
  • [35] PEDIATRIC CLINICAL-PHARMACOLOGY OF DIGOXIN
    SOYKA, LF
    PEDIATRIC CLINICS OF NORTH AMERICA, 1981, 28 (01) : 203 - 216
  • [36] Neonatal and Pediatric Clinical Pharmacology Preface
    van den Anker, John N.
    Coppes, Max J.
    Koren, Gideon
    PEDIATRIC CLINICS OF NORTH AMERICA, 2012, 59 (05) : XV - XVIII
  • [37] PERSPECTIVES IN PEDIATRIC CLINICAL-PHARMACOLOGY
    MACLEOD, SM
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 129 - 130
  • [38] PEDIATRIC CLINICAL PHARMACOLOGY AND THERAPEUTIC ORPHAN
    DONE, AK
    COHEN, SN
    STREBEL, L
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1977, 17 : 561 - 573
  • [39] CYCLOPHOSPHAMIDE (CYTOXAN) - A REVIEW ON RELEVANT PHARMACOLOGY AND CLINICAL USES
    AHMED, AR
    HOMBAL, SM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 11 (06) : 1115 - 1126
  • [40] Evaluation of dexmedetomidine safety and dosing for outpatient pediatric electroencephalogram.
    Huang, Letha
    Whitmore, Maria
    Goldman, Mitchell
    Mohr-Eslinger, Nicole
    Schounce, Davaina
    PHARMACOTHERAPY, 2016, 36 (07): : E98 - E98